Indication
In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive.
Medicine details
- Medicine name:
- quizartinib (Vanflyta)
- SMC ID:
- SMC2699
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- 11 November 2024
- Patient group submission deadline:
- 02 September 2024